FAP-targeted radioligand therapy with <sup>68</sup>Ga/<sup>177</sup>Lu-DOTA-2P(FAPI)<sub>2</sub> enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy
Our study robustly advocates for use of FAP-targeting radiopharmaceuticals, particularly <sup>177</sup>Lu-DOTA-2P(FAPI)<sub>2</sub>, alongside immunotherapy in treating FAP-positive tumors. This combination therapy transforms the TME and enables a translatable approach to increasing the sensitivity to PD-1/PD-L1 immunotherapy, leading to improved complete remission rates and extended overall survival.
Authors
- Liang Zhao (ORCID: https://orcid.org/0000-0002-1303-8775)
- Long Sun (ORCID: https://orcid.org/0000-0002-3869-4832)
- Yangfan Zhou (ORCID: https://orcid.org/0000-0002-6726-0523)
- Haojun Chen (ORCID: https://orcid.org/0000-0002-9101-8884)
- Hua Wu (ORCID: https://orcid.org/0000-0002-4210-2377)
- Guoqiang Su (ORCID: https://orcid.org/0000-0001-8833-3931)
- Yizhen Pang (ORCID: https://orcid.org/0000-0001-7710-5925)
- Qin Lin (ORCID: https://orcid.org/0000-0002-4391-8706)
- Xiaoyuan Shawn Chen (ORCID: https://orcid.org/0000-0002-9622-0870)
- Kaili Fu
- Jian‐Hao Chen (ORCID: https://orcid.org/0000-0003-0540-1092)
- Qicong Luo (ORCID: https://orcid.org/0000-0002-3282-5336)
Institutions
- Agency for Science, Technology and Research (SG)
- National University of Singapore (SG)
- First Affiliated Hospital of Xiamen University (CN)
- Jiaxing University (CN)
- Institute of Molecular and Cell Biology (SG)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-010212
- Citations
- 23
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 24.04
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province